ArticleJournal of aerosol medicine and pulmonary drug delivery2018
Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Article in Journal of aerosol medicine and pulmonary drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
In-vivo Deposition Measurement of Beclometasone and Formoterol After Inhalation of a Single Dose of the Combination BDP Plus Formoterol NEXT DPI in Healthy Volunteers, Asthmatic and COPD Patients.
The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and Dyspnea is Associated to the Improvement in Small Airway Dysfunction in COPD Patients. A Pilot Study (IOSCOPD20161102)
Measurement of Breathing Parameters of Asthma and COPD Patients With Different Degrees of Disease Severity for the Computer Simulation of Lung Deposition of Aerosol Drugs
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Lung Deposition and Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease Using Different Inhalation Devices: A Systematic Literature Review and Expert Opinion.International journal of chronic obstructive pulmonary diseasePooled it
- Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers.Clinical and translational science · 2022Trial
- Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.Respiratory research · 2021Trial
- Symptoms improvement and lung function benefits of fixed triple therapy with beclomethasone/formoterol/glycopyrronium inhalation powder in patients with moderate-to-severe COPD: outcomes of the Bulgarian arm of the RESPONSE study.Journal of thoracic disease · 2026Article
- Optimizing Respiratory Care with NEXThaler: Bridging Technology and Treatment.Medical devices (Auckland, N.Z.) · 2026Review
- Effects of inhaled bronchodilators on dynamic lung mechanics during exercise in COPD: protocol for a randomised, placebo-controlled crossover trial.ERJ open research · 2025Article
- Lung Deposition of Extrafine Versus Nonextrafine Aerosols at Low Inhalation Flow Rates in Adult Asthma Patients: A Composition Study.Journal of aerosol medicine and pulmonary drug delivery · 2025Article
- Small scale electrostatically-driven aerosol deposition inFrontiers in physiology · 2025Article
- Non-local impact of distal airway constrictions on patterns of inhaled particle deposition.Royal Society open science · 2024Article
- The effects of airway disease on the deposition of inhaled drugs.Expert opinion on drug delivery · 2024Review
- Aerosol Plumes of Inhalers Used in COPD.Pulmonary therapy · 2024Article
- Feedback systems in multi-dose dry powder inhalers.Postepy dermatologii i alergologii · 2023Review
- Aerosolised micro and nanoparticle: formulation and delivery method for lung imaging.Clinical and translational imaging · 2023Review
- BDP/FF NEXThaler to Improve Asthma Control Status in the Real World: The NEWTON Study.Journal of asthma and allergy · 2023Article
- Experimental Evaluation of Dry Powder Inhalers during Inhalation and Exhalation Using a Model of the Human Respiratory System (xPULM™).Pharmaceutics · 2022Article
- Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study.Journal of aerosol medicine and pulmonary drug delivery · 2021Article
- Pulmonary Drug Delivery of Antimicrobials and Anticancer Drugs Using Solid Dispersions.Pharmaceutics · 2021Review
- Beclomethasone/Formoterol in Extra-Fine Formulation Improves Small Airway Dysfunction in COPD Patients.Pulmonary therapy · 2021Article
- Measurements of deposited aerosol dose in infants and small children.Annals of translational medicine · 2021Review
- High-Efficiency Dry Powder Aerosol Delivery to Children: Review and Application of New Technologies.Journal of aerosol science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the lung deposition and the distribution pattern in the airways of a fixed combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) (100/6 μg) delivered as an extrafine dry powder formulation (mass median aerodynamic diameter, MMAD (μm) BDP = 1.5; FF = 1.4) through the NEXThaler
methodsHealthy subjects (n = 10), asthmatic patients (n = 9; 30%≤FEV
resultsNo significant difference in drug deposition was observed between the three study groups. Mean lung deposition, extrathoracic deposition, and amount exhaled ranged, respectively, between 54.9% and 56.2%, between 41.8% and 43.2%, and between 1.6% and 3.3% of BDP emitted dose (71.7 ± 2.5 μg) for the three study groups. The central to peripheral ratio (reflecting the lung distribution pattern) ranged between 1.23 and 2.02 for the three study groups, indicating a distribution of the drug throughout the airways, including periphery. The study treatment produced a forced expiratory volume in one second (FEV
conclusionsThe fixed extrafine dry powder combination BDP/FF (100/6 μg) administered through the DPI NEXThaler
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.